Proteomic profiling of the autoimmune response to breast cancer antigens uncovers a suppressive effect of hormone therapy

Proteomics - Clinical Applications

Volumn 7, Issue 5-6, 2013, Pages 327-336

  Chao, Timothy ^a   Ladd, Jon J ^a   Qiu, Ji ^a   Johnson, Melissa M ^a   Israel, Rebecca ^a   Chin, Alice ^a   Wang, Hong ^a   Prentice, Ross L ^a   Feng, Ziding ^a   Disis, Mary L ^b   Hanash, Samir ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Autoantibodies; Autoimmunity; Breast cancer; Hormone therapy

Indexed keywords

ESTROGEN; FIBROBLAST GROWTH FACTOR 2; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN G; INTERLEUKIN 1 RECEPTOR TYPE I; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 7; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; PROGESTERONE; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ADULT; AGED; ANTIBODY RESPONSE; ARTICLE; AUTOIMMUNITY; CANCER CELL; CANCER HORMONE THERAPY; CONTROLLED STUDY; CYTOKINE RESPONSE; DRUG EFFICACY; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; HORMONE SUBSTITUTION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEOMICS; TUMOR IMMUNITY;

ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS, HORMONAL; AUTOANTIBODIES; AUTOIMMUNITY; BLOOD PROTEINS; BREAST NEOPLASMS; CELL LINE, TUMOR; CHEMOKINES; CYTOKINES; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSION; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MCF-7 CELLS; PROTEIN ARRAY ANALYSIS; PROTEOMICS;

EID: 84879444202     PISSN: 18628346     EISSN: 18628354     Source Type: Journal    
DOI: 10.1002/prca.201200058     Document Type: Article

References (43)

1. Forrester, S., Qiu, J., Mangold, L., Partin, A. et al., Ion experimental strategy for quantitative analysis of the humoral immune response to prostate cancer antigens using natural protein microarrays. Proteomics Clin. Appl. 2007, 1, 494-505.
2. Katayama, H., Paczesny, S., Prentice, R., Aragaki, A. et al., Application of serum proteomics to the Women's Health Initiative conjugated equine estrogens trial reveals a multitude of effects relevant to clinical findings. Genome Med. 2009, 1, 47.
3. Pitteri, S., Hanash, S., Aragaki, A., Amon, L. et al., Postmenopausal estrogen and progestin effects on the serum proteome. Genome Med. 2009, 1, 121.
4. Pitteri, S. J., Hanash, S. M., Confounding effects of hormone replacement therapy in protein biomarker studies. Cancer Epidemiol. Biomar. Prevent. 2011, 20, 134-139.
5. Anderson, G. L., Limacher, M., Assaf, A. R., Bassford, T. et al., Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. J. Am. Med. Assoc. 2004, 291, 1701-1712.
6. Rossouw, J. E., Anderson, G. L., Prentice, R. L., LaCroix, A. Z. et al., Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. J. Am. Med. Assoc. 2002, 288, 321-333.
7. Wassertheil-Smoller, S., Hendrix, S. L., Limacher, M., Heiss, G. et al., Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. J. Am. Med. Assoc. 2003, 289, 2673-2684.
8. Hendrix, S. L., Wassertheil-Smoller, S., Johnson, K. C., Howard, B. V. et al., Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation 2006, 113, 2425-2434.
9. Cauley, J. A., Robbins, J., Chen, Z., Cummings, S. R. et al., Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. J. Am. Med. Assoc. 2003, 290, 1729-1738.
10. Jackson, R. D., Wactawski-Wende, J., LaCroix, A. Z., Pettinger, M. et al., Effects of conjugated equine estrogen on risk of fractures and BMD in postmenopausal women with hysterectomy: results from the women's health initiative randomized trial. J. Bone. Miner. Res. 2006, 21, 817-828.
11. Chlebowski, R. T., Hendrix, S. L., Langer, R. D., Stefanick, M. L. et al., Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. J. Am. Med. Assoc. 2003, 289, 3243-3253.
12. Stefanick, M. L., Anderson, G. L., Margolis, K. L., Hendrix, S. L. et al., Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. J. Am. Med. Assoc. 2006, 295, 1647-1657.
13. Hall, P., Ploner, A., Bjohle, J., Huang, F. et al., Hormone-replacement therapy influences gene expression profiles and is associated with breast-cancer prognosis: a cohort study. BMC Med. 2006, 4, 16.
14. Georgiadou, P., Sbarouni, E., Effect of hormone replacement therapy on inflammatory biomarkers. Adv. Clin. Chem. 2009, 47, 59-93.
15. Miller, A. P., Chen, Y. F., Xing, D., Feng, W., Oparil, S., Hormone replacement therapy and inflammation: interactions in cardiovascular disease. Hypertension 2003, 42, 657-663.
16. Castanho, V. S., Gidlund, M., Nakamura, R., de Faria, E. C., Post-menopausal hormone therapy reduces autoantibodies to oxidized apolipoprotein B100. Gynecol. Endocrinol. 2011, 27, 800-806.
17. Desmetz, C., Bascoul-Mollevi, C., Rochaix, P., Lamy, P. J. et al., Identification of a new panel of serum autoantibodies associated with the presence of in situ carcinoma of the breast in younger women. Clin. Cancer Res. 2009, 15, 4733-4741.
18. Goodell, V., Disis, M. L., Human tumor cell lysates as a protein source for the detection of cancer antigen-specific humoral immunity. J. Immunol. Methods 2005, 299, 129-138.
19. Madoz-Gurpide, J., Kuick, R., Wang, H., Misek, D. E., Hanash, S. M., Integral protein microarrays for the identification of lung cancer antigens in sera that induce a humoral immune response. Mol. Cell. Proteomics 2008, 7, 268-281.
20. Pereira-Faca, S., Qiu, J., Krasnoselsky, A., Newcomb, L., Hanash, S., Proteomic identification of tumor antigens in lung cancer. Mol. Cell. Proteomics 2005, 4, S125-S125.
21. Qiu, J., Choi, G., Li, L., Wang, H. et al., Occurrence of autoantibodies to annexin I, 14-3-3 theta and LAMR1 in prediagnostic lung cancer sera. J. Clin. Oncol. 2008, 26, 5060-5066.
22. Nam, M. J., Kee, M. K., Kuick, R., Hanash, S. M., Identification of defensin alpha 6 as a potential biomarker in colon adenocarcinoma. J. Biol. Chem. 2005, 280, 8260-8265.
23. Nam, M. J., Madoz-Gurpide, J., Wang, H., Lescure, P. et al., Molecular profiling of the immune response in colon cancer using protein microarrays: occurrence of autoantibodies to ubiquitin C-terminal hydrolase L3. Proteomics 2003, 3, 2108-2115.
24. Bouwman, K., Qiu, J., Zhou, H. P., Schotanus, M. et al., Microarrays of tumor cell derived proteins uncover a distinct pattern of prostate cancer serum immunoreactivity. Proteomics 2003, 3, 2200-2207.
25. Hong, S. H., Misek, D. E., Wang, H., Puravs, E. et al., An autoantibody-mediated immune response to calreticulin isoforms in pancreatic cancer. Cancer Res. 2004, 64, 5504-5510.
26. Pitteri, S. J., JeBailey, L., Faca, V. M., Thorpe, J. D. et al., Integrated proteomic analysis of human cancer cells and plasma from tumor bearing mice for ovarian cancer biomarker discovery. PLoS One 2009, 4, e7916.
27. Qiu, J., Hanash, S., Autoantibody profiling for cancer detection. Clin. Lab. Med. 2009, 29, 31-46.
28. Qiu, J., Choi, G., Li, L., Wang, H. et al., Occurrence of autoantibodies to annexin I, 14-3-3 theta and LAMR1 in prediagnostic lung cancer sera. J. Clin. Oncol. 2008, 26, 5060-5066.
29. He, P., Naka, T., Serada, S., Fujimoto, M. et al., Proteomics-based identification of alpha-enolase as a tumor antigen in non-small lung cancer. Cancer Sci. 2007, 98, 1234-1240.
30. Weiskopf, D., Weinberger, B., Grubeck-Loebenstein, B., The aging of the immune system. Transpl. Int. 2009, 22, 1041-1050.
31. Somiari, R. I., Sullivan, A., Russell, S., Somiari, S. et al., High-throughput proteomic analysis of human infiltrating ductal carcinoma of the breast. Proteomics 2003, 3, 1863-1873.
32. Tu, S. H., Chang, C. C., Chen, C. S., Tam, K. W. et al., Increased expression of enolase alpha in human breast cancer confers tamoxifen resistance in human breast cancer cells. Breast Cancer Res. Tr. 2010, 121, 539-553.
33. Chu, P. Y., Hsu, N. C., Liao, A. T., Shih, N. Y. et al., Overexpression of alpha-enolase correlates with poor survival in canine mammary carcinoma. BMC Vet. Res. 2011, 7, 62.
34. Mojtahedi, Z., Safaei, A., Yousefi, Z., Ghaderi, A., Immunoproteomics of HER2-positive and HER2-negative breast cancer patients with positive lymph nodes. OMICS 2011, 15, 409-418.
35. Kariagina, A., Xie, J., Leipprandt, J. R., Haslam, S. Z., Amphiregulin mediates estrogen, progesterone, and EGFR signaling in the normal rat mammary gland and in hormone-dependent rat mammary cancers. Horm. Cancer 2010, 1, 229-244.
36. Mead, M. N., Estrogens shield breast cancer cells. Environ. Health Persp. 2007, 115, A297.
37. d'Elia, H. F., Carlsten, H., The impact of hormone replacement therapy on humoral and cell-mediated immune responses in vivo in post-menopausal women with rheumatoid arthritis. Scand. J. Immunol. 2008, 68, 661-667.
38. Eilertsen, A. L., Sandvik, L., Steinsvik, B., Sandset, P. M., Differential impact of conventional-dose and low-dose postmenopausal hormone therapy, tibolone and raloxifene on C-reactive protein and other inflammatory markers. J. Thromb. Haemost. 2008, 6, 928-934.
39. Kooperberg, C., Cushman, M., Hsia, J., Robinson, J. G. et al., Can biomarkers identify women at increased stroke risk? The women's health initiative hormone trials. PLoS Clin. Trials 2007, 2.
40. Rossouw, J. E., Cushman, M., Greenland, P., Lloyd-Jones, D. M. et al., Inflammatory, lipid, thrombotic, and genetic markers of coronary heart disease risk in the Women's Health Initiative Trials of Hormone Therapy. Arch. Intern. Med. 2008, 168, 2245-2253.
41. Straub, R. H., Hense, H. W., Andus, T., Scholmerich, J. et al., Hormone replacement therapy and interrelation between serum interleukin-6 and body mass index in postmenopausal women: a population-based study. J. Clin. Endocrinol. Metabol. 2000, 85, 1340-1344.
42. Murooka, T. T., Rahbar, R., Fish, E. N., CCL5 promotes proliferation of MCF-7 cells through mTOR-dependent mRNA translation. Biochem. Biophys. Res. Commun. 2009, 387, 381-386.
43. Pinilla, S., Alt, E., Abdul Khalek, F. J., Jotzu, C. et al., Tissue resident stem cells produce CCL5 under the influence of cancer cells and thereby promote breast cancer cell invasion. Cancer Lett. 2009, 284, 80-85.